Proteomics International Laboratories (ASX:PIQ) Total Liabilities : A$1.74 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Proteomics International Laboratories Total Liabilities?

Proteomics International Laboratories's Total Liabilities for the quarter that ended in Dec. 2024 was A$1.74 Mil.

Proteomics International Laboratories's quarterly Total Liabilities declined from Dec. 2023 (A$1.72 Mil) to Jun. 2024 (A$1.63 Mil) but then increased from Jun. 2024 (A$1.63 Mil) to Dec. 2024 (A$1.74 Mil).

Proteomics International Laboratories's annual Total Liabilities declined from Jun. 2022 (A$2.00 Mil) to Jun. 2023 (A$1.75 Mil) and declined from Jun. 2023 (A$1.75 Mil) to Jun. 2024 (A$1.63 Mil).

Proteomics International Laboratories Total Liabilities Historical Data

The historical data trend for Proteomics International Laboratories's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proteomics International Laboratories Total Liabilities Chart

Proteomics International Laboratories Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Total Liabilities

Get a 7-Day Free Trial

1.12

0.99

2.00

1.75

1.63

Proteomics International Laboratories Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Liabilities	Get a 7-Day Free Trial															1.80	1.75	1.72	1.63	1.74

Proteomics International Laboratories Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Proteomics International Laboratories's Total Liabilities for the fiscal year that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.905	+	(0.221	+	-1.1102230246252E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0.379	+	0.121	+	0)
	=	1.63

Total Liabilities	=	Total Assets (A: Jun. 2024 )	-	Total Equity (A: Jun. 2024 )
	=	10.875	-	9.249
	=	1.63

Proteomics International Laboratories's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.201	+	(0.118	+	0.424
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1.74

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	7.021	-	5.278
	=	1.74

Proteomics International Laboratories Total Liabilities Related Terms

Thank you for viewing the detailed overview of Proteomics International Laboratories's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Proteomics International Laboratories Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Proteomics International Laboratories Ltd (ASX:PIQ) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Verdun Street, QEII Medical Centre, QQ Block, Nedlands, Perth, WA, AUS, 6009

Website

https://www.proteomics.com.au

Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.

Proteomics International Laboratories Headlines

No Headlines